Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion thoracic stent graft system. The device is indicated for the minimally invasive repair of all lesions of the descending thoracic aorta, including thoracic aortic aneurysms (TAA), blunt thoracic aortic injuries (BTAI), penetrating atherosclerotic ulcers (PAU), intramural hematomas (IMH) and aortic type B dissections (TBAD).

Giving birth is associated with a 14 percent higher risk of heart disease and stroke compared to having no children, reports a study published in the European Journal of Preventive Cardiology. EJPC is a journal of the European Society of Cardiology (ESC).

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Omron Healthcare Inc. and physIQ Inc. announced a collaboration to integrate Omron’s HeartGuide wearable blood pressure monitoring device into the pinpointIQ platform to monitor at-risk patients in an outpatient setting. The strategic collaboration aims to generate actionable clinical information for at-risk patients in an outpatient environment by leveraging the complementary technologies of each company.

Canon Medical Systems USA Inc. recently introduced a new angiography configuration featuring its Alphenix Sky + C-arm and Hybrid Catheterization Tilt/Cradle Table for interventional procedures with its Aquilion One/Genesis Edition computed tomography (CT) system. The new pairing, called the Alphenix 4-D CT, allows clinicians to efficiently plan, treat and verify in a single clinical setting. The flexible hybrid system enables streamlined workflow and extensive range of patient access and coverage.

Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.

Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufactured Dec. 26, 2017, to April 19, 2018 due, to incorrect assembly that reversed the catheter lumens. This recall includes 1,426 devices in the United States.

February 5, 2019 – The American Society of Echocardiography (ASE) released a new document that provides a comprehensive review of the optimal application of transesophageal echocardiography (TEE) for patients with congenital heart disease (CHD).

Stroke survivors have better quality of life three months after their stroke if the clot that caused the stroke was mechanically removed even hours beyond the ideal treatment window compared to those treated with drugs alone. This preliminary research will be presented, Feb. 6-8 in Honolulu at the American Stroke Association’s International Stroke Conference 2019.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now